AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 IV day 1
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 IV day 1
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
Study NCT02130414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmun® IV
Description: 2 mg/kg IV
Study NCT02130414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyCol® capsules
Description: 37.5 mg CyCol® capsules
Study NCT04291144 — intervention group
Intervention type: RADIATION
Intervention: PET-CT using FEOBV
Description: We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
Study NCT04291144 — intervention group
Intervention type: RADIATION
Intervention: MRI-scan
Description: All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.
Study NCT04291144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessment
Description: Full neuropsychometric examination including tests in 5 cognitive domains.
Study NCT04291144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment
Description: Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
Study NCT02119520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin +Atorvastatin
Study NCT02119520 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Platelet rich fibrin
Study NCT02119520 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: open flap debridement
Study NCT01349647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Description: Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
Study NCT01349647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Description: Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16.
Study NCT04653519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtually guided minimally invasive preparation
Description: Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
Study NCT04088448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
Study NCT04088448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
Study NCT00806104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides
Description: Dietary supplementation for 4 weeks
Study NCT00806104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrins
Description: Dietary supplementation for 4 weeks
Study NCT02862691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Oxycodone (Oral analgesic)
Description: 2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
Study NCT02982408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel.
Study NCT02862691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine (Injectable local anesthetic)
Description: local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
Study NCT02803957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord DS1000
Description: Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
Study NCT02803957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Mitral Valve Repair
Description: Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 monotherapy
Description: MK0518 twice daily for 10 days
Study NCT02982408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal physical activity
Description: The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior.
Study NCT02468258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial flushing
Description: Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
Study NCT04128826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Using the cable machine, shoulders will be flexed to 180° for both (PROM \& FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
Study NCT00431600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% Oxygen
Description: 100% Oxygen- breathing over 30 minutes
Study NCT02533479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: three alternate days weekly along 4 weeks.
Study NCT01115465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Macroplastique
Description: Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518 combination therapy
Description: MK0518 twice daily for 48 weeks
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: efavirenz
Description: efavirenz 600 mg every night at bedtime for 48 weeks
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: tenofovir
Description: tenofovir 300 mg daily for 48 weeks
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks
Study NCT04089592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
Study NCT04089592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: intravenous fentanyl at 2mcg/kg in 100ml saline
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: lamivudine
Description: lamivudine 300 mg daily for 48 weeks
Study NCT00100048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo monotherapy
Description: Placebo to MK0518 twice daily
Study NCT04123821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Description: A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
Study NCT01453881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spacer
Description: Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
Study NCT01453881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
Study NCT05595538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple doses of anti-SARS-CoV-2 Convalescent Plasma
Description: SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
Study NCT03496753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Led Therapy
Description: The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
Study NCT02047669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biopsychosocial
Study NCT02047669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Study NCT02960282 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of fecal specimens
Study NCT02960282 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04550026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HTP inhalation
Description: Sham inhalation for 30 minutes
Study NCT04550026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HTP inhalation
Description: Sham inhalation for 30 minutes
Study NCT04472728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO101
Description: BIO101 capsules
Study NCT04472728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study NCT06237023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: epidemyolojical
Description: The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.
Study NCT02992574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post Mastectomy Radiation therapy
Description: Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
Study NCT04598542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR)
Description: 0.07 mg
Study NCT04598542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Description: 40 mg
Study NCT01576640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NRT
Description: Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
Study NCT01576640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion SR 150mg bid
Description: Subjects were given bupropion SR 150 mg bid throughout the course of the study.
Study NCT01942746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Juice S2
Description: Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
Study NCT01942746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Capsules S2
Description: Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
Study NCT01942746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule S2
Description: Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
Study NCT01942746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice L1
Description: Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
Study NCT01942746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Juice L1
Description: Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
Study NCT01518972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study NCT01518972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study NCT02042365 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS (Enhanced recovery after surgery)
Study NCT01576640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relapse Prevention-Oriented Cognitive Behavioral Therapy
Description: Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
Study NCT04272593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
Study NCT04272593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
Study NCT03585140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal diet
Description: The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
Study NCT03585140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic diet
Description: The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
Study NCT03585140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% Gel
Description: Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
Study NCT03585140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene 0.1% Gel
Description: Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
Study NCT03585140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100 mg per day orally, before breakfast
Study NCT03585140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg per day orally, before breakfast
Study NCT03390140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReInventing Yourself after SCI structured group CBT
Description: ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
Study NCT03390140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReInventing Yourself after SCI study-specific workbook
Description: A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
Study NCT03390140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReInventing Yourself after SCI study-specific workbook
Description: A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
Study NCT03390140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReInventing Yourself after SCI YouTube videos
Description: YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
Study NCT03983499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Description: The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)